Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 6, 2026

Is Salesforce or ServiceNow a Better Stock to Buy Right Now?

View original at finance.yahoo.com
Is Salesforce or ServiceNow a Better Stock to Buy Right Now? Software stocks spent the first part of 2026 among the market's weakest names…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Salesforce guided full fiscal year 2027 revenue of approximately $45.9 billion to $46.2 billion, representing approximately 11% total growth, of which only about 8 percentage points is organic with Informatica contributing the remainder

    60% confidence
  • Annual recurring revenue from Agentforce surpassed $1 billion for the first time, up 205% year over year

    60% confidence
  • Salesforce's Q1 FY2027 revenue growth of 13% was an acceleration from the 9% growth reported two quarters earlier, though part of that lift came from the Informatica acquisition

    60% confidence
  • After a roughly 30% year-to-date decline, Salesforce now trades at a price-to-earnings ratio of about 22, which represents a reasonable valuation

    60% confidence
  • Slack was nearly half of Salesforce's million-plus customer wins in Q1 FY2027, up 80% year-over-year

    60% confidence
  • Investors worried that AI agents would chip away at the per-seat licensing model on which much of enterprise software is built, driving the sector's early-2026 selloff

    60% confidence

Data points we hold from this source

Salesforce · margin34.8 percent
Salesforce · margin32.3 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
Is Salesforce or ServiceNow a Better Stock to Buy Right Now? — Source | Via News | ViaNews Market